Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies
2022-501648-14-00Phase 2Authorised
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Nov 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zamtocabtagene autoleucel, MB-CART20.1 and zorpocabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 1 more, sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Late-onset adverse reactions, serious adverse events, serious adverse reactions, adverse events of special interest. Planned start Nov 2023; status: authorised.
02
Drugs
zamtocabtagene autoleucelMB-CART20.1zorpocabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)melanoma
Beyond the preview
Go deeper on 2022-501648-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501648-14-00.